Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection

T. H. Senanayake, S. Gorantla, E. Makarov, Y. Lu, G. Warren, S. V. Vinogradov

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Nucleoside reverse transcriptase inhibitors (NRTIs) are an integral part of the current antiretroviral therapy (ART), which dramatically reduced the mortality from AIDS and turned the disease from lethal to chronic. The further steps in curing the HIV-1 infection must include more effective targeting of infected cells and virus sanctuaries inside the body and modification of drugs and treatment schedules to reduce common complications of the long-term treatment and increase patient compliancy. Here, we describe novel NRTI prodrugs synthesized from cholesteryl-ε-polylysine (CEPL) nanogels by conjugation with NRTI 5′-succinate derivatives (sNRTI). Biodegradability, small particle size, and high NRTI loading (30% by weight) of these conjugates; extended drug release, which would allow a weekly administration schedule; high therapeutic index (>1000) with a lower toxicity compared to NRTIs; and efficient accumulation in macrophages known as carriers for HIV-1 infection are among the most attractive properties of new nanodrugs. Nanogel conjugates of zidovudine (AZT), lamivudine (3TC), and abacavir (ABC) have been investigated individually and in formulations similar to clinical NRTI cocktails. Nanodrug formulations demonstrated 10-fold suppression of reverse transcriptase activity (EC90) in HIV-infected macrophages at 2-10, 2-4, and 1-2 μM drug levels, respectively, for single nanodrugs and dual and triple nanodrug cocktails. Nanogel conjugate of lamivudine was the most effective single nanodrug (EC90 2 μM). Nanodrugs showed a more favorable pharmacokinetics compared to free NRTIs. Infrequent iv injections of PEGylated CEPL-sAZT alone could efficiently suppress HIV-1 RT activity to background level in humanized mouse (hu-PBL) HIV model.

Original languageEnglish (US)
Pages (from-to)4226-4236
Number of pages11
JournalMolecular Pharmaceutics
Volume12
Issue number12
DOIs
StatePublished - Nov 2 2015

Fingerprint

Reverse Transcriptase Inhibitors
Nucleosides
HIV Infections
Antiviral Agents
HIV-1
Polylysine
Lamivudine
Appointments and Schedules
Macrophages
HIV
Zidovudine
RNA-Directed DNA Polymerase
Prodrugs
Succinic Acid
Therapeutics
NanoGel
Particle Size
Pharmaceutical Preparations
Acquired Immunodeficiency Syndrome
Pharmacokinetics

Keywords

  • HIV-1
  • abacavir
  • epsilon-polylysine
  • humanized mouse (hu-PBL) HIV model
  • lamivudine
  • macrophages
  • mitochondrial toxicity
  • nanogel conjugates
  • nucleoside reverse transcriptase inhibitors
  • prodrugs of zidovudine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection. / Senanayake, T. H.; Gorantla, S.; Makarov, E.; Lu, Y.; Warren, G.; Vinogradov, S. V.

In: Molecular Pharmaceutics, Vol. 12, No. 12, 02.11.2015, p. 4226-4236.

Research output: Contribution to journalArticle

@article{07bbb6fa32504023a833750712deba4f,
title = "Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection",
abstract = "Nucleoside reverse transcriptase inhibitors (NRTIs) are an integral part of the current antiretroviral therapy (ART), which dramatically reduced the mortality from AIDS and turned the disease from lethal to chronic. The further steps in curing the HIV-1 infection must include more effective targeting of infected cells and virus sanctuaries inside the body and modification of drugs and treatment schedules to reduce common complications of the long-term treatment and increase patient compliancy. Here, we describe novel NRTI prodrugs synthesized from cholesteryl-ε-polylysine (CEPL) nanogels by conjugation with NRTI 5′-succinate derivatives (sNRTI). Biodegradability, small particle size, and high NRTI loading (30{\%} by weight) of these conjugates; extended drug release, which would allow a weekly administration schedule; high therapeutic index (>1000) with a lower toxicity compared to NRTIs; and efficient accumulation in macrophages known as carriers for HIV-1 infection are among the most attractive properties of new nanodrugs. Nanogel conjugates of zidovudine (AZT), lamivudine (3TC), and abacavir (ABC) have been investigated individually and in formulations similar to clinical NRTI cocktails. Nanodrug formulations demonstrated 10-fold suppression of reverse transcriptase activity (EC90) in HIV-infected macrophages at 2-10, 2-4, and 1-2 μM drug levels, respectively, for single nanodrugs and dual and triple nanodrug cocktails. Nanogel conjugate of lamivudine was the most effective single nanodrug (EC90 2 μM). Nanodrugs showed a more favorable pharmacokinetics compared to free NRTIs. Infrequent iv injections of PEGylated CEPL-sAZT alone could efficiently suppress HIV-1 RT activity to background level in humanized mouse (hu-PBL) HIV model.",
keywords = "HIV-1, abacavir, epsilon-polylysine, humanized mouse (hu-PBL) HIV model, lamivudine, macrophages, mitochondrial toxicity, nanogel conjugates, nucleoside reverse transcriptase inhibitors, prodrugs of zidovudine",
author = "Senanayake, {T. H.} and S. Gorantla and E. Makarov and Y. Lu and G. Warren and Vinogradov, {S. V.}",
year = "2015",
month = "11",
day = "2",
doi = "10.1021/acs.molpharmaceut.5b00424",
language = "English (US)",
volume = "12",
pages = "4226--4236",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection

AU - Senanayake, T. H.

AU - Gorantla, S.

AU - Makarov, E.

AU - Lu, Y.

AU - Warren, G.

AU - Vinogradov, S. V.

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Nucleoside reverse transcriptase inhibitors (NRTIs) are an integral part of the current antiretroviral therapy (ART), which dramatically reduced the mortality from AIDS and turned the disease from lethal to chronic. The further steps in curing the HIV-1 infection must include more effective targeting of infected cells and virus sanctuaries inside the body and modification of drugs and treatment schedules to reduce common complications of the long-term treatment and increase patient compliancy. Here, we describe novel NRTI prodrugs synthesized from cholesteryl-ε-polylysine (CEPL) nanogels by conjugation with NRTI 5′-succinate derivatives (sNRTI). Biodegradability, small particle size, and high NRTI loading (30% by weight) of these conjugates; extended drug release, which would allow a weekly administration schedule; high therapeutic index (>1000) with a lower toxicity compared to NRTIs; and efficient accumulation in macrophages known as carriers for HIV-1 infection are among the most attractive properties of new nanodrugs. Nanogel conjugates of zidovudine (AZT), lamivudine (3TC), and abacavir (ABC) have been investigated individually and in formulations similar to clinical NRTI cocktails. Nanodrug formulations demonstrated 10-fold suppression of reverse transcriptase activity (EC90) in HIV-infected macrophages at 2-10, 2-4, and 1-2 μM drug levels, respectively, for single nanodrugs and dual and triple nanodrug cocktails. Nanogel conjugate of lamivudine was the most effective single nanodrug (EC90 2 μM). Nanodrugs showed a more favorable pharmacokinetics compared to free NRTIs. Infrequent iv injections of PEGylated CEPL-sAZT alone could efficiently suppress HIV-1 RT activity to background level in humanized mouse (hu-PBL) HIV model.

AB - Nucleoside reverse transcriptase inhibitors (NRTIs) are an integral part of the current antiretroviral therapy (ART), which dramatically reduced the mortality from AIDS and turned the disease from lethal to chronic. The further steps in curing the HIV-1 infection must include more effective targeting of infected cells and virus sanctuaries inside the body and modification of drugs and treatment schedules to reduce common complications of the long-term treatment and increase patient compliancy. Here, we describe novel NRTI prodrugs synthesized from cholesteryl-ε-polylysine (CEPL) nanogels by conjugation with NRTI 5′-succinate derivatives (sNRTI). Biodegradability, small particle size, and high NRTI loading (30% by weight) of these conjugates; extended drug release, which would allow a weekly administration schedule; high therapeutic index (>1000) with a lower toxicity compared to NRTIs; and efficient accumulation in macrophages known as carriers for HIV-1 infection are among the most attractive properties of new nanodrugs. Nanogel conjugates of zidovudine (AZT), lamivudine (3TC), and abacavir (ABC) have been investigated individually and in formulations similar to clinical NRTI cocktails. Nanodrug formulations demonstrated 10-fold suppression of reverse transcriptase activity (EC90) in HIV-infected macrophages at 2-10, 2-4, and 1-2 μM drug levels, respectively, for single nanodrugs and dual and triple nanodrug cocktails. Nanogel conjugate of lamivudine was the most effective single nanodrug (EC90 2 μM). Nanodrugs showed a more favorable pharmacokinetics compared to free NRTIs. Infrequent iv injections of PEGylated CEPL-sAZT alone could efficiently suppress HIV-1 RT activity to background level in humanized mouse (hu-PBL) HIV model.

KW - HIV-1

KW - abacavir

KW - epsilon-polylysine

KW - humanized mouse (hu-PBL) HIV model

KW - lamivudine

KW - macrophages

KW - mitochondrial toxicity

KW - nanogel conjugates

KW - nucleoside reverse transcriptase inhibitors

KW - prodrugs of zidovudine

UR - http://www.scopus.com/inward/record.url?scp=84949036026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949036026&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.5b00424

DO - 10.1021/acs.molpharmaceut.5b00424

M3 - Article

C2 - 26565115

AN - SCOPUS:84949036026

VL - 12

SP - 4226

EP - 4236

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 12

ER -